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Tamoxifen is the most often prescribed hormonal therapy for the
treatment of hormone-dependent, oestrogen receptor (ER)/proges-
terone receptor (PR) positive breast cancer. However, approxi-
mately half of all breast cancers do not respond to hormonal
therapy and these hormone-independent tumours are more diffi-
cult to manage. Hormone-independent breast cancer is encoun-
tered in the following settings: 1. following long-term therapy with
the antioestrogen tamoxifen, often termed acquired resistance, 2.
initially tamoxifen non-responsive despite the tumour expressing
ER, and 3. tumours classified as ER negative upon diagnosis. The
latter two categories are referred to as de novo resistant, or
hormone-independent. These three classifications of tumours
represent the most aggressive forms of breast cancer and an effec-
tive treatment modality is not yet available. We and others have
explored the basis of tamoxifen resistance by examining key steps
along the ER-mediated signal transduction pathway (Encarnacion
et al, 1993; Johnston et al, 1993; Osborne, 1993; Wolf et al, 1993;
Karnik et al, 1994; Wolf and Jordan, 1994; Tonetti and Jordan,
1995). However, to date, examination of this pathway has yielded
relatively few clues concerning the molecular mechanism of
tamoxifen resistance. Identification of a suitable molecular target
in these tumour types would facilitate the development of a logical
therapeutic approach.
It is well documented that ER and protein kinase C (PKC)
activity and abundance is inversely related in breast cancer cell
lines (Borner et al, 1987) and PKC is elevated in malignant versus
normal breast tissue (Borner et al, 1987; O’Brian et al, 1989;
Gordge et al, 1996). Furthermore increased AP-1 (activator
protein-1) activity has been reported to occur in hormone-indepen-
dent breast cancer cell lines and tumours (Dumont et al, 1996;
Johnston et al, 1999). PKC is a family of serine-threonine protein
kinases which is now comprised of at least 11 isozymes, α , β I, β II,
γ , δ , ε , ζ , η , θ , ι /λ and µ (Dekker and Parker, 1994), and is a known
upstream activator of the AP-1 signal transduction pathway. These
isozymes have been categorized into three groups based mainly on
their co-factor requirements and sequence similarity, substrate
specificity, and marked tissue and intracellular distribution
(Nishizuka, 1992; Kazanietz et al, 1993). Activation of PKCs by
the tumour promoter 12-O-tetradecanoylphorbol-13-acetate (TPA)
results in the expression of the c-fos and c-jun family of nuclear
protooncogenes, and increased transcriptional activity of genes
containing a TPA-responsive element (TRE) (Angel and Karin,
1991). The AP-1 complex, comprised of either a Fos-Jun
heterodimer or a Jun-Jun homodimer, binds to the TRE and
induces gene transcription (Angel et al, 1987b; Lee et al, 1987).
PKC isozymes differ in their ability to mediate transcriptional
activation through the TRE (Hata et al, 1993; Reifel-Miller et al,
1996). TPA, which specifically binds to and activates PKC, causes
down-regulation of the ER by post-transcriptional destabilization
of the mRNA (Saceda et al, 1991) and inhibition of ER function
(Martin et al, 1995). Furthermore, since ER and PKC expression is
inversely related (Borner et al, 1987), it is possible that PKC could
play a fundamental role in the slip from hormone-dependent to
hormone-independent breast cancer.
Therefore, there is sufficient evidence in the literature indicating
an involvement of ER and PKC in AP-1 activation. In this study
we have examined PKC isozyme expression and AP-1 activation
in two hormone-independent human breast cancer cell lines,
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compared with their respective hormone-dependent counterparts,
MCF-7 A4(WS8) and T47D:A18. We find the hormone-indepen-
dent cell lines overexpress PKCα and have elevated basal AP-1
activity. To determine whether PKCα overexpression is sufficient
to create both the hormone-independent phenotype and induce
elevated basal AP-1 activity, we stably transfected PKCα into the
hormone-dependent T47D:A18 and MCF-7 A4 cell lines.
Transfection of PKCα into MCF-7 cells was previously reported
by two independent investigators (Ways et al, 1995; Manni et al,
1996). Ways et al report that overexpression of PKCα caused a
reduction in ER expression, decreased oestrogen-dependent gene
expression and a more aggressive neoplastic phenotype. In
contrast, Manni et al. reported a less aggressive phenotype in
MCF-7 cells as a result of PKCα overexpression. Since we have
both hormone-dependent and -independent pairs of each cell type,
we set out to determine the effect of PKCα overexpression in
T47D cells compared to MCF-7. This question is especially rele-
vant since T47D cells lose the ER more readily (Pink et al, 1996)
and form tamoxifen-resistant tumours in athymic mice at an accel-
erated rate compared with MCF-7 cells (MacGregor-Schaffer et al,
2000). In consideration of the well-documented inverse relation-
ship between ER and PKC, T47D cells provide a more appropriate
cellular context in which to address the role of PKCα overexpres-
sion on the hormone-dependent phenotype. We find that in
T47D:A18 cells overexpressing PKCα , there is concomitant up-
regulation of PKC β I and δ , whereas in MCF-7 A4/PKCα trans-
fectants PKCε is up-regulated. In T47D:A18, but not in MCF-7
A4, PKCα stable transfection is accompanied by down-regulation
of ER function whilst basal AP-1 activity is elevated. PKCα stable
transfection is not sufficient, however, to allow the antioestrogen
tamoxifen to switch on the AP-1 pathway in either T47D:A18 or
MCF-7:A4 cells. These results suggest that in the breast cancer
cell lines T47D:A18 and MCF-7 A4, PKCα , and consequently β I,
δ and ε overexpression, is not sufficient to trigger AP-1 activation,
and is not likely to singly lead to tamoxifen-stimulated tumour
growth. However, PKCα overexpression does lead to decreased
ER function, and may play a role in de novo hormone-independent
breast cancers.
MATERIALS AND METHODS
Cell lines and culture conditions
MCF-7 WS8 and T47D:A18 are hormone-dependent human
breast cancer cell clones that have been previously described
(Jiang et al, 1992; Pink et al, 1996). MCF-7 A4 is a hormone-
dependent single cell clone of MCF-7 cells obtained from the
American Type Culture Collection (ATCC, Rockville, MD). MCF-
7 WS8, A4 and T47D:A18 were maintained in phenol red-
containing RPMI-1640 medium supplemented with 10% FBS as
previously described (Jiang et al, 1992; Pink et al, 1996). The
hormone-independent MCF-7 5C cell clone was maintained in
phenol red-free MEM supplemented with 5% 3 × dextran-coated
charcoal (DCC)-treated calf serum (oestrogen-free media) as
previously described (Jiang et al, 1992). The hormone-indepen-
dent T47D:C42 clone was passaged in phenol red-free RPMI-1640
supplemented with 10% 3 × DCC-treated FBS (oestrogen-free
media) as previously described (Pink et al, 1996). Prior to transient
transfection experiments and RNA isolation, all cell lines were
placed in oestrogen-free media for 3 days.
Poly A+ RNA isolation and Northern blot
Total RNA was isolated from cell lines using the Trizol reagent
(GibcoBRL, Rockville, MD) prior to isolation of poly A+ RNA
using the PolyATract mRNA isolation kit (Promega, Madison, WI).
Equal amounts of polyA+ RNA were loaded per lane (4–5 µ g),
electrophoresed in a 1% agarose-0.66M formaldehyde gel, trans-
ferred to a Magnagraph nylon membrane (MSI, Westborough, MA)
and the RNA was fixed to the membrane by UV cross-linking. The
PKC  α ,  δ ,  ε and  η cDNA clones were obtained from ATCC
(Rockville, MD) and the following cDNA fragments were labelled
with [α -32P]dCTP by random priming: a 1.3 Kb Eco RI PKC α
fragment from phPKC-α 7; a 1.7 Kb Eco RI PKC δ fragment from
the I.M.A.G.E. Consortium Clone ID 236079; a 2.2 Kb Nhe I PKC
ε fragment from pBluebac/PKC ε ; a 1.7 Pvu II PKC fragment from
pAcMP3/PKC eta. Equivalent loading of mRNA in each lane was
verified by stripping and reprobing with β -actin cDNA.
Partial PKC Purification and Western Blot
A PKC-enriched fraction was purified from at least 4 x 108 cells by
DEAE-cellulose anion exchange column chromatography as
previously described  (Tonetti et al., 1992).  Protein concentration
was measured using the Bio-Rad Dc protein assay system (Bio-Rad
Laboratories, Hercules, CA). A SDS-8% polyacrylamide gel was
loaded with equal amounts of protein (50-100 µ g/lane) and pre-
stained molecular weight standards to approximate the protein size.
Following electrophoresis, protein was transferred to Hybond-ECL
nitrocellulose membranes (Amersham Life Sciences, Buching-
hamshire, England) by semi-dry electroblot transfer.  PKC
isozyme-specific monoclonal (PKCα , Transduction Laboratories,
Lexington, KY) and polyclonal antibodies β I, β II, δ , ε , η , Santa
Cruz Biotechnology, Santa Cruz, CA), were diluted as follows in
TBS-T (20 mM Tris, pH 7.6; 137 mM NaCl; 0.1% Tween 20)
containing 5% dry milk: α , 1:1000; β I, β II and δ , 1:500; ε , η , 1:250.
The ECL Western blotting detection system (Amersham Life
Science) was used to visualise the PKC bands. Equal loading of
total protein per lane was assessed by Coomassie Brilliant Blue
staining of a gel run in parallel or by stripping and reprobing with a
β -actin monoclonal antibody (Sigma Chemical, St. Louis, MO).
Generation of MCF-7 and T47D PKCα stable
transfectants
The pSPKCα expression plasmid was generously provided by Dr
Kirk Ways (Lilly Research Laboratories) (Reifel-Miller et al,
1996). MCF-7 A4 or T47D:A18 cells were suspended in serum-
free medium (1 × 107 cells/ml), mixed with 10 µ g plasmid DNA
and electroporated (250 V, 950 µ F). The transfection mixture was
added to 10 ml RPMI media (phenol red +) containing 10% FBS
and seeded into 100 mm tissue culture dishes. Following incuba-
tion for 2 days, the medium was replaced with medium containing
G418 (500 µ g/ml media). The range of transfection efficiencies
was approximately one G418-resistant transfectant/104-105 MCF-7
or T47D cells, and one-third all G418-resistant T47D and one
fourth of all G418-resistant MCF-7 cells also overexpressed
PKCα . Individual colonies were picked following 3 weeks of
selection and were screened for PKCα expression by Western blot.
Cells were transfected with the pSVHNX-neo plasmid as a
control. The clones designated MCF7/neo, MCF7/α 12,
MCF7/α 29 and T47D:A18/neo, T47D:A18/α 5 and T47D:A18/
α 20 were chosen for further characterization.
The role of PKC alpha in hormone-independent breast cancer 783
British Journal of Cancer (2000) 83(6), 782–791 © 2000 Cancer Research CampaignProliferation assay
The cell lines T47D:A18/neo, T47D:A18/PKCα 5 and
T47D:A18/PKCα 20 were seeded at 3 × 104 cells/ml in either
phenol red-containing RPMI media or phenol red-free RPMI (for
determination of hormone-independent proliferation) supple-
mented with 500 µ g/ml G418 into T25 tissue culture flasks. Cells
were counted on days 2–10.
Growth assays
Cells were grown in oestrogen-free media for 2 days prior to each
experiment and were seeded into 24-well plates (15 000
cells/well) (Day 0). The following day (Day 1) medium containing
either ethanol (control), E2 (10–13–10–7 M) or 4-OHT (10–12–10–6
M) was added. All compounds were dissolved in 100% ethanol
and added to the medium at a 1:1000 dilution. Medium was
changed on Days 3 and 5. DNA content was determined on Day 6
using a fluorocolorimeter (Labarca and Paigen, 1980).
ER protein expression
Nuclear extracts were prepared from MCF-7A4 and T47D:A18
cell clones using a freeze-thaw method (Chen et al, 1996). ER
expression was assessed by Western blot analysis using the ER
mouse monoclonal antibody AER311 (human cross-reactive)
(Neomarkers, Fremont, CA) followed by band detection with the
ECL Western blotting kit (Amersham).
Transient transfections and luciferase activity
A TRE-tk-Luc reporter plasmid was constructed by inserting a
synthetic TRE derived from the human collagenase gene (5′
ATGAGTCAGA 3′ ) in tandem (4 copies) into the pT109luc vector
(Nordeen, 1988). The ERE-tk-Luc plasmid contains three tandem
copies of the vitellogenin ERE sequence inserted into pT109luc
(Catherino and Jordan, 1995). Either the TRE-tk-luc or ERE-tk-
luc plasmid was transiently co-transfected with the β -galactosi-
dase (β -gal) expression plasmid pCMVβ (for the purpose of
transfection efficiency normalization) into both the MCF-7 and the
T47D:A18 stable clones by electroporation. Fifteen to 18 hours
following transfection, the TRE-tk-Luc transfected cells were
treated with either phorbol 12-myristate 13-acetate (PMA) (10–7
M); 4-hydroxytamoxifen (4-OHT) (10–7 M) or 17β -oestradiol (E2)
(10–9 M). The ERE-tk-Luc transfected cells were treated with E2
(10–9 M), 4-OHT (10–7 M), or ICI 182,780 (10–7 M). Luciferase
and β -gal activity was assayed 20 hours (ERE-tk-Luc transfection)
or 5 and 20 hours (TRE-tk-Luc) following treatment using the
Dual-Light Assay System (Tropix).
Statistical analysis
When comparing to 1 as in Figures 4 and 9A, data were analysed
using a one sample, one-tailed t-test. When comparing groups,
data were analysed using one-way analysis of variance.
Significant differences were indicated when P < 0.05.
RESULTS
PKC expression in hormone-dependent and hormone-
independent breast cancer cell lines
Elevated PKC expression (upstream activator of AP-1) is reported
to correlate with hormone-independent breast cancer (Wyss et al,
1987; O’Brian et al, 1989; Davidson and Kennedy, 1996; Gordge
et al, 1996). We have examined two pairs of hormone-dependent
and hormone-independent human breast cancer cell lines to
determine whether a particular PKC isozyme(s) is associated with
hormone independence. MCF-7 5C and T47D:C42 cell clones
were derived from their respective parental cell lines MCF-7 and
T47D by long-term culture in oestrogen-free media (Jiang et al,
1992; Pink et al, 1996) and are both E2 and antioestrogen (4-OHT
and ICI 164,384) insensitive. The T47D:C42 cell clone has lost 
the expression of ERα , whereas the MCF7 5C cell clone exhibits
reduced ERα expression (Figure 1) and impaired ER function
(Jiang et al, 1992). We have compared PKC isozyme expression in
these two hormone-independent breast cancer cell lines with their
respective hormone-dependent counterpart cell clones, MCF-7
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Figure 1 ERα expression in hormone-dependent and hormone-
independent breast cancer cell lines. Nuclear extracts were prepared from all
breast cancer cell lines and a Western blot was performed using the ERα -
specific monoclonal antibody, AER-311, that recognizes a 67 kDa protein.
Equivalent protein loading was assessed by stripping the membrane and 
re-probing with a β -actin monoclonal antibody
PKC alpha
PKC epsilon
b-actin
PKC alpha
PKC epsilon
b-actin
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CE
WS8
OC E
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Figure 2 PKC isozyme mRNA expression in hormone-dependent and
hormone-independent human breast cancer cell lines. PolyA+ RNA was
isolated (as described in ‘Materials and Methods’) following 24 hours
treatment: C, control (ethanol vehicle); E, E2 10–9 M; O, 4-OHT 10–7 M. 
A Northern blot was done by hybridization with PKCα , ε and β -actin cDNAs.
(A) MCF-7 clones WS8 (hormone-dependent) and 5C (hormone-
independent). (B) T47D clones A18 (hormone-dependent) and C42
(hormone-independent). Approximate sizes of specific messages were as
follows: PKCα – 9.5, 3.7 and 3.2 kb; PKCε – 7.4 and 6.8. These results were
reproduced at least three times and the Northern blot shown is a
representative experimentThe role of PKC alpha in hormone-independent breast cancer 785
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A4(WS8) and T47D:A18, by both Northern and Western blot
analysis.
PKC α , δ , ε , and η mRNAs were detected in all of the cell lines
by Northern blot. The hormone-independent MCF-7 5C exhibits
elevated expression of the PKCα transcripts compared with the
hormone-dependent WS8 clone (Figure 2A). The MCF-7 WS8
and 5C clones express similar levels of PKC ε (Figure 2A) δ and η
mRNAs (results not shown). Treatment of these cell clones with
either E2 or 4-OHT did not alter the expression level of the PKCα
isozyme transcripts examined, however there is a slight up-regula-
tion of PKCε in response to E2 treatment (Figure 2A). Similarly,
whereas the T47D:A18 (ER-positive, hormone-dependent) and
C42 (ER-negative, hormone-independent) clones express compa-
rable levels of PKC δ and η mRNAs in the untreated, E2 or 4-
OHT-treated conditions (results not shown), PKC α and ε mRNAs
are more abundant in the hormone-independent T47D C42 cell
line (Figure 2B). In particular, expression of PKCα mRNA is
undetectable in the T47D:A18 cells in contrast to the abundant
expression observed in the T47D:C42 cell clone, whereas only a
smaller PKC ε mRNA is more abundant in the C42 cells compared
with A18. Therefore, whereas the hormone-dependent cell clones
(MCF-7 WS8 and T47D A18) express very low or undetectable
levels of PKC α and ε mRNAs, the hormone-independent MCF-7
5C and T47D C42 express comparatively more abundant PKC α
and ε transcript expression.
To determine whether the abundance of PKC α and ε mRNA
expression is reflected in the amount of protein produced, we
examined PKC isozyme expression by Western blot analysis. The
relative PKCα protein levels expressed in MCF-7 5C compared
with MCF-7 A4 correspond to the PKCα transcript abundance
observed; PKCα protein is expressed at higher levels in the
hormone-independent MCF-7 5C cells (Figure 3A). PKC ε protein
is more abundant in MCF-7 5C compared with the A4, whereas
the PKC ε basal mRNA levels are comparable (Figure 2A). There
is no difference in PKC β I expression.
Accordingly, the overexpression of PKCα mRNAs directly
correlates with the PKCα protein levels expressed in T47D:A18
and C42; PKCα protein is more abundant in the hormone-indepen-
dent C42 cells relative to the A18 cells (Figure 3B). There is no
difference in PKC ε or  η expression and PKC δ is barely
detectable (results not shown) in the T47D clones.
Induction of AP-1 transcriptional activation
Elevated AP-1 activity is associated with tamoxifen-resistant
breast cancer (Astruc et al, 1995; Dumont et al, 1996; Smith et al,
1999). Since PKC is a known upstream activator of the AP-1
pathway, we compared the amount of basal and treatment-induced
AP-1 activity in the hormone-dependent and hormone-indepen-
dent breast cancer cell lines. Following transient co-transfection of
the TRE-tk-luc and pCMVβ -gal plasmids, the MCF-7 A4, 5C and
T47D:A18, C42 cell lines were either untreated (control, ethanol
vehicle) or treated with PMA (10–7 M), E2 (10–9 M) or 4-OHT
(10–7 M) for 5 and 24 hours prior to determining luciferase and β -
gal activities. Basal AP-1 activity was elevated in both of the
hormone-independent cell clones MCF-7 5C and T47D:C42
compared with their hormone-dependent counterparts MCF-7 A4
and T47D:A18 (Figure 4A). The basal AP-1 activity of the MCF-
7 5C cell clone was 7-fold higher than the MCF-7 A4 clone,
although this did not achieve statistical significance at the P < 0.05
level. However, the basal AP-1 activity of T47D:C42 was elevated
2.6-fold compared with T47D:A18 (P < 0.05). Treatment of the
cells with 10–7 M PMA (activator of PKC) for 5 hours caused an
induction of AP-1 activity in all cells lines, verifying the function-
ality of the reporter construct (Figures 4B and 4C). PMA induced
AP-1 activity to a greater extent in MCF-7 A4 cells compared with
MCF-7 5C cells (16-fold vs 5-fold) (Figure 4B), most likely due to
the fact that MCF-7 5C cells already exhibit high basal AP-1
activity. PMA-induced AP-1 activation was comparable (2-fold)
in both T47D:A18 and C42 cell lines. Neither E2 nor 4-OHT treat-
ment of any of the cell lines resulted in transcriptional activation
of AP-1 at 5 h (Figures 4B and 4C) or 24 h (results not shown). We
can conclude that the hormone-independent breast cancer cell
lines (MCF-7 5C and T47D C42) have elevated basal AP-1
activity compared with their hormone-dependent counterparts
(MCF-7 A4 and T47D A18). However this activity is not regulated
by E2 or 4-OHT treatment.
Stable transfection of PKCα in hormone-dependent
T47D:A18 and MCF-7 A4 breast cancer cells
Since we have determined that both hormone-independent cell
lines overexpress PKCα , we set out to determine the role of this
isozyme in hormone-independent breast cancer. Therefore, we
stably transfected the PKCα expression plasmid, pSPKCα , into
MCF-7 A4 and T47D:A18 cells. After screening several clones for
PKCα expression by Western blotting, we chose to further charac-
terise two clones from each cell line, MCF-7 A4/PKCα 12 and α 29
and T47D:A18/PKCα 5 and α 20.
To determine whether overexpression of PKCα would affect the
expression of other PKC isozymes, we performed Western blots
using antibodies recognizing PKC β I, δ , and ε (Figure 5). We find
that in MCF-7, overexpression of PKCα causes concomitant up-
regulation of PKC ε . This pattern of PKC isozyme expression is
similar to the MCF-7 5C cell line (Figure 3A). In the T47D:A18
cell line however, PKC β I and δ are up-regulated (Figure 5),
whereas this PKC expression pattern is not evident in the
T47D:C42 cell line. Cross-regulation between PKCα and β was
previously reported in MCF-7 cells (Ways et al, 1995; Manni et al,
1996), however cross-regulation between PKCα and PKCs δ and ε
has not been reported.
A4
MCF-7
5C A18
T47D
C42
PKC epsilon
b-actin
PKC epsilon
PKC beta I
PKC alpha
PKC alpha
PKC eta
Figure 3 PKCα protein expression in MCF-7 and T47D cell clones. A PKC-
enriched fraction was isolated from the MCF-7 (A) and T47D (B) breast
cancer cell lines and analysed by Western blot using specific antibodies to
PKCα , β I, and ε isozymes, recognizing 82 kDa, 80 kDa and 90 kDa proteins,
respectively. Equivalent protein loading was assessed by stripping the
membrane and re-probing with a β -actin monoclonal antibody
B AThe oestrogen-dependent phenotype of MCF-7
A4/PKCα and T47D:A18/PKCα stable transfectants
To examine whether the previously characterized inverse rela-
tionship of PKC and ER expression exists in our PKCα stable
transfectants, we examined cell growth in response to E2, E2-
induced transcriptional activation of an oestrogen response
element (ERE), and ERα protein expression. Growth assays
were performed measuring DNA content as the endpoint. We
find that the T47D:A18/PKCα transfectants have a reduced
oestrogen-induced growth response compared with the
T47D:A18/neo control. Whereas the T47D:A18/neo cells
demonstrated a 5-fold increase cell growth over the control, the
PKCα stable clones exhibited only a 2-fold induction of growth
following E2 treatment (Figure 6A). 4-OHT did not differen-
tially affect the growth of T47D:A18/neo versus PKCα transfec-
tants and was capable of competitively inhibiting the E2-induced
growth response (results not shown). No difference in E2-
(Figure 6B) nor 4-OHT-(results not shown) induced cell growth
was apparent comparing the MCF-7 A4/neo, MCF-7A4/PKCα 12
or α 29 cell clones.
Transcriptional activation of an ERE was measured by transient
transfection of an ERE-luciferase reporter plasmid into each 
cell line and luciferase activity was measured following 24 hour
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Figure 4 Transcriptional activation of AP-1 in hormone-dependent and
hormone-independent breast cancer cell lines. (A) Basal AP-1 transcriptional
activity of MCF-7 A4, 5C and T47D:A18 and C42 cell clones. The TRE-tk-luc
and pCMVβ plasmids were co-transfected into MCF-7 A4, 5C and T47D:A18,
C42 breast cancer cell clones. Luciferase and β -gal activity was determined
(as described in ‘Material and Methods’). Normalized luciferase activity of the
hormone-independent cell clones (MCF-7 5C and T47D A18) is expressed
relative to their respective hormone-dependent cell clones (MCF-7 A4 and
T47D C42, set = 1). (B) AP-1 transcriptional activation in response to PMA,
E2 and 4-OHT in MCF-7 cell clones A4 and 5C, (C) T47D cell clones A18
and C42. Fifteen to 18 h following electroporation, the cells were treated with
either ethanol vehicle (Control), PMA (10–7 M), E2 (10–9 M) or 4-OHT 
(10–7 M). Luciferase and β -gal activities were measured 5 hours following
treatment. The range of raw luciferase units obtained for all experiments for
each cell line were as follows: MCF7 A4, 4703–15, 951; MCF-7 5C, 14,
103–125,588; T47D:A18, 800–2968; T47D:C42, 1114–2847. The background
luciferase activity (transfection of pT109luc plasmid without AP-1 element)
was between 150–200 raw luciferase units. All data is expressed as the
normalized luciferase activity (mean ± SE) of 3 independent experiments
performed in triplicate. A one sample, one-tailed t-test was used to determine
significance compared to 1. *Indicates significance at P < 0.05
neo
MCF7 T47D:A18
a12 a19 neo a5 a20
PKC alpha
PKC beta I
PKC delta
PKC epsilon
b-actin
Figure 5 Western blot analysis of PKC isozyme expression in T47D:A18
and MCF-7 A4 PKCα stable cell clones. PKC protein was partially purified
from MCF-7 A4 and T47D:A18 neo and PKCα stable clones by DEAE-
cellulose chromatography as described in Materials and Methods. Western
blot analysis was performed using specific antibodies to PKCα , β I, δ , and ε
isozymes recognizing 82, 80, 78 and 90 kDa proteins respectively. Equivalent
protein loading was assessed by stripping the membrane and re-probing with
a β -actin monoclonal antibodyThe role of PKC alpha in hormone-independent breast cancer 787
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treatment with E2. The ability of the T4D:A18/PKCα clones to
activate transcription of an ERE-luciferase reporter plasmid was
abrogated by an order of magnitude compared with the
T47D:A18/neo clone (Figure 7A). Luciferase activity was induced
200-fold in the neo transfectants compared with only a 20-fold
induction in the PKCα transfectants. The MCF-7 A4 clones
however, displayed no difference in the ability to activate the
ERE-tk-luc plasmid compared with the neo transfected control
(Figure 7B). These results indicate an inverse relationship of
PKCα and ER function in T47D:A18 cells as assessed by E2-
induced growth response and activation of an ERE. The MCF-7
A4/PKCα clones, however, do not exhibit this inverse relationship
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Figure 7 ERE transcriptional activation in response to E2 in T47D:A18/PKCα and MCF-7/PKCα stable clones. ERE-TK-luc and pCMVβ plasmids were
transiently co-transfected by electroporation into T47D:A18 (A) and MCF-7 (B) stable transfectants. Twenty-four hours following electroporation, the cells were
treated with either ethanol vehicle (Control), E2 (10–9 M) or ICI 182,780 (10–7 M). Luciferase and β -gal activity was measured 20 hours following treatment. Data
is expressed as the normalized E2-induced fold-increase over ICI 182,780 treatment (mean ± SE) of 3 independent experiments performed in triplicate. Data
were analysed by one-way ANOVA. *Indicates significant difference among groups at P = 0.0263as was previously reported (Ways et al, 1995). Our results in MCF-
7 cells may be due to either an insufficient level of PKCα to
produce this effect, or may be attributed to differences in the
particular MCF-7 cell clones used in the two laboratories.
Alternatively, it may be the fact that PKCα overexpression in
T47D:A18 leads to increased PKC β I and δ levels, whereas the
MCF-7 A4/PKCα transfectants overexpress PKC ε .
To determine whether the impaired ER function in the
T47D:A18/PKCα clones as exhibited by the reduced E2-induced
growth response and transcriptional activation of an ERE was due to
loss of ER expression, ERα protein levels were assessed by Western
blotting. The T47D:A18 neo and PKCα 5 clones appear to express
comparable ERα , whereas the PKCα 20 shows a slight decrease in
ERα protein (Figure 8). This result suggests that although ERα
protein is expressed, functionality is impaired by PKCα , and
perhaps β I and δ over-expression. No difference in ERα levels were
observed in the MCF-7 A4 transfectants (results not shown).
Basal AP-1 activity in T47D:A18/PKCα stable
transfectants
Since basal AP-1 activity is elevated in the hormone-independent
T47D:C42 clone compared to T47D:A18, and T47D:C42 over-
expresses PKCα , we wanted to determine whether the basal AP-1
activity was also elevated in the PKCα stable transfectants. We
transiently transfected a TRE-luciferase reporter construct that
contained four tandem repeats of the collagenase TRE sequence
(Angel et al, 1987a). The PKCα clones exhibited 6–7-fold higher
basal AP-1 activity compared with the neo transfectant (Figure
9A). These results suggest that overexpression of PKCα , and
perhaps β and δ , is sufficient to raise the basal AP-1 activity to
levels comparable to that of the hormone-independent T47D:C42
cell line. It is interesting to note that T47D:C42 cells do not exhibit
PKC β I nor δ overexpression (results not shown). The MCF-7 
A4 transfectants showed no increase in AP-1 basal activity (results
not shown).
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Figure 9 AP-1 transcriptional activity of T47D:A18/PKCα stable clones. 
TRE-tk-luc and pCMVβ plasmids were transiently co-transfected by
electroporation into T47D:A18/neo and PKCα stable transfectants.
Luciferase and β -gal activity was measured 40 hours following transfection.
(A) Basal AP-1 transcriptional activity shown as the normalized luciferase
activity (luciferase/β -gal) of the PKCα clones expressed relative to the
T47D:A18/neo clone (set = 1). *Indicates statistical significance at P < 0.05
using one-sample t-test. (B) AP-1 transcriptional activation in response to
PMA and 4-OHT in T47D:A18/PKCα stable clones. Twenty-four hours
following electroporation the cells were treated with either ethanol vehicle
(control); PMA (10–7 M) or 4-OHT (10–7 M). Luciferase and β -gal activity was
measured 20 hours following treatment. Data is expressed as the normalized
luciferase activity (mean ± SE) of 3 independent experiments performed in
triplicate. Data were analysed by one-way ANOVA. *Indicates statistical
difference among groups treated with PMA at P = 0.044
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)4-OHT is incapable of activating AP-1 in
T47D:A18/PKCα transfectants
We examined the ability of PMA, which is a potent PKC and AP-1
activator, to induce transcription of the TRE-tk-Luc reporter in the
T47D:A18/PKCα transfectants. As we expected, the
T47D:A18/PKCα transfectants exhibited a 6–8-fold higher AP-1
activation in response to PMA compared with the neo transfected
T47D:A18 cells (Figure 9B). It was previously reported that
tamoxifen is capable of activating AP-1 following long-term
antioestrogen treatment of breast cancer cells in a PKC-dependent
manner (Astruc et al, 1995). We hypothesized that PKC up-regula-
tion may be a prerequisite step to tamoxifen-stimulated growth.
Therefore we examined whether PKCα overexpression in
T47D:A18 is sufficient to allow 4-OHT to activate AP-1. We
found that 4-OHT did not activate AP-1 in these T47D:A18/PKCα
transfectants (Figure 9B). This result is not surprising since the
T47D:C42 (Pink et al, 1995) and T47D:A18/PKCα cell clones
exhibit a hormone-independent phenotype and not a tamoxifen-
stimulated phenotype.
T47D:A18/PKCα proliferative rate
It was previously reported that overexpression of PKCα in MCF-7
cells leads to an increased proliferative rate compared to neo trans-
fected MCF-7 cells (Ways et al, 1995). The T47D:A18/PKCα
stable transfectants appear to have a similar growth rate as the
T47D:A18/neo up until day 5. However after 5 days,
T47D:A18/PKCα 5 and α 20 can grow to a higher cell density than
the neo transfectant (Figure 10A). After 10 days, the
T47D:A18/PKCα 5 and α 20 cell clones have not yet reached satu-
ration density at 1.9 × 107 and 2.4 × 107 total cells respectively, and
appear to be in good condition and remain attached to the plate. In
contrast, the T47D:A18/neo cells at day 10 (1.4 × 107 total cells)
are beginning to detach from the plate and the remaining cells are
in poor condition.
To determine whether PKCα overexpression is sufficient to
confer hormone-independent growth we examined the rate of
proliferation in oestrogen-free medium. We find that both
T47D:A18/PKCα clones are able to grow at a statistically
significant faster rate than the T47D:A18/neo clone in the absence
of oestrogen between days 5–10 (Figure 10B).
DISCUSSION
Approximately one half of all breast cancers are hormone-
independent, and will not respond to hormonal therapy. Although
tamoxifen is the endocrine treatment of choice for ER/PR positive
breast cancers of all stages, eventually most tumours will become
refractory to this therapy and the disease will recur. Based on
reports in the literature, activation of the AP-1 signal transduction
pathway may be involved in hormone-independent and tamoxifen-
resistant breast cancers (Astruc et al, 1995; Webb et al, 1995;
Dumont et al, 1996; Johnston et al, 1999; Smith et al, 1999). To
explore this possible mechanism, we examined the PKC isozyme
expression profile and AP-1 activity of MCF-7 and T47D breast
cancer cell clone pairs that are hormone-dependent and -indepen-
dent. We report a particular PKC isozyme, PKCα , is commonly
overexpressed in both of the hormone-independent cell clones and
is associated with elevated AP-1 activity. We established stable
PKCα transfectants in the hormone-dependent T47D:A18 and
MCF-7 A4 cell lines to determine whether PKCα overexpression
is sufficient to confer elevated AP-1 activity and hormone-
independence. We find that the T47D:A18/PKCα clones exhibited
decreased ER function, increased hormone-independent growth
rate, decreased contact inhibition and elevated basal AP-1 activity
whereas the MCF-7/PKCα clones showed no effect on ER func-
tion or AP-1 activity.
The observation that ER and PKC expression are inversely
related has been previously reported (Borner et al, 1987). In partic-
ular, inverse expression of PKCα and ER is reported in several
breast cancer cell lines, and is associated with increased cell inva-
sion (Morse-Gaudio et al, 1998; Platet et al, 1998; Johnson et al,
1999; Ng et al, 1999; Sun and Rotenberg, 1999). PKCα and ERα
are inversely related in the hormone-independent cell lines
T47D:C42 and MCF-7 5C. The T47D:C42 cells have lost the
expression of ERα and express elevated PKCα protein, whereas
the MCF-7 5C cells have reduced ERα expression, concomitant
with elevated PKCα expression (Figures 1–3). ER function is
The role of PKC alpha in hormone-independent breast cancer 789
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likely impaired in the 5C cells since oestrogen-stimulated PR
expression and activation of an ERE-reporter construct is dramati-
cally reduced in 5C cells (Jiang et al, 1992).
Other laboratories have previously reported stable transfection
and overexpression of PKCα in the MCF-7 breast cancer cell line.
Ways et al (1995) reported that MCF-7/PKCα stable transfectants
exhibited reduced expression of the ER and of oestrogen-respon-
sive genes, and resulted in a more aggressive neoplastic pheno-
type. Interestingly Manni et al (1996) reported that transfection of
MCF-7 with PKCα produced no concomitant reduction in ER
expression, and induced a less aggressive phenotype. These
contrasting reports were attributed in part to differences in the
expression of other PKC isozymes; Ways et al report upregulation
of PKCβ , and downregulation of PKCs δ and η , whereas the trans-
fectants described by Manni et al overexpressed only α and β
isozymes (Manni et al, 1996). We find our MCF-7 5C cells over-
express PKCα , and unlike either study, PKC ε (Figure 3A).
Similar to 5C cells, the MCF-7 A4/PKCα transfectants over-
express both PKCα and ε . Despite the fact that MCF-7 5C cells
exhibit non-functional ER (reduced ERE activation, absence of
E2-induced cell growth), the MCF-7/PKCα transfectants exhib-
ited intact ER function. These results are in contrast to those of
Ways et al (1995). Interestingly the T47D:A18/PKCα transfec-
tants exhibited cross-up-regulation of PKC β I and δ , loss of ER
function, increased AP-1 activity, hormone-independent growth
and increased saturation density. This is the first report of PKCα
transfection in T47D cells and is in agreement with the results in
MCF-7 cells reported by Ways et al (1995). Our inability to
observe these effects in MCF-7 may be due to either differences in
MCF-7 clones, or perhaps insufficient levels of PKCα expression
were achieved.
It has been reported that the AP-1 pathway may be activated by
long-term tamoxifen treatment (Astruc et al, 1995) and tamoxifen-
resistant breast cancer is associated with elevated AP-1 activity
(Dumont et al, 1996; Johnston et al, 1999). Since PKCα is known
to play a role in AP-1 signalling (Hata et al, 1993; Reifel-Miller et
al, 1996), we investigated this pathway. It is important to point out,
however, that the cell lines utilized in this study are hormone-inde-
pendent. They were derived by long-term culture in oestrogen-free
media and do not represent a model for long-term tamoxifen treat-
ment. Although it was previously reported that both E2 and 4-
OHT are capable of activating the AP-1 pathway (Astruc et al,
1995; Webb et al, 1995), E2 and 4-OHT did not induce AP-1
activity in either the MCF-7 nor T47D PKCα cell clones (Figure
4B and C). This is in contrast to the previous reports showing that
E2 induces a 2-fold induction of an AP-1 reporter plasmid in
MCF-7 cells (Philips et al, 1993; Webb et al, 1995). In addition, 4-
OHT has been reported to activate AP-1 in a cell-type specific
manner, it acts as an agonist in endometrial cell lines, but not in
breast cell lines (Webb et al, 1995). In addition, prolonged treat-
ment of MCF-7 cells with 4-OHT (4–12 days) was reported to
activate an AP-1 reporter plasmid (Astruc et al, 1995). Clearly our
hormone-independent cell clones have not been treated with 4-
OHT long-term nor represent a model of tamoxifen-stimulated
growth, and therefore such a response may not be expected.
Based on our results and others (Astruc et al, 1995; Webb et al,
1995; Dumont et al, 1996), activation of the AP-1 signal transduc-
tion pathway is a likely mechanism of hormone-independent
breast cancer. We hypothesise that in the transition from tamox-
ifen-responsive to tamoxifen-resistant breast cancer, or in the case
of de novo hormone-independent breast cancers, perhaps the equi-
librium shifts from predominantly ER-mediated signalling to AP-1
signalling. The report of Webb et al (1995) provided evidence that
the antioestrogen/ER complex can interact with the AP-1 compo-
nents through a protein:protein interaction. However, in those
cases of hormone-independence due to loss of ER or a non-func-
tional ER, PKCα up-regulation may be an alternate route to AP-1
activation. At present the mechanism of PKCα up-regulation as
well as the specific intermediate steps leading towards AP-1 acti-
vation are unknown. We suggest that perhaps the overexpression
of PKCα may be a prerequisite step in initiating this switch in
signalling. To directly test this hypothesis, we are using antisense
technology to downregulate PKCα expression in tamoxifen-stimu-
lated breast tumours in athymic mice in an attempt to abrogate
tamoxifen-stimulated tumour growth. We have preliminary
evidence that the T47D:A18/PKCα clones form tumours in
ovariectomised athymic mice both in response to tamoxifen and in
the absence of estrogen supplementation (Tonetti, unpublished
observations). We are in the process of characterising these
tumours. Identification of a specific PKC isozyme as a potential
therapeutic target would be an important advance in the manage-
ment of hormone-independent breast cancer.
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